MNOV Medicinova Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MNOV

Price (delayed)

$2.8

Market cap

$137.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.21

Enterprise value

$112.52M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 17

MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and ...

Highlights
The gross margin has soared by 177% YoY
The company's revenue has surged by 54% QoQ
The quick ratio has contracted by 34% YoY and by 3.7% from the previous quarter
The equity has declined by 20% year-on-year and by 5% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://medicinova.com
Peers: LLY ALKS TEVA NVS

Key stats

What are the main financial stats of MNOV

MNOV stock price

How has the Medicinova stock price performed over time
Intraday
-3.45%
1 week
11.11%
1 month
101.44%
1 year
120.47%
YTD
113.74%
QTD
112.12%

Financial performance

How have Medicinova's revenue and profit performed over time
Revenue
$920,481
Gross profit
$347,443
Operating income
-$11.85M
Net income
-$10.75M
Gross margin
37.7%
Net margin
-1,168.2%
The gross margin has soared by 177% YoY
The net margin has soared by 87% YoY and by 41% from the previous quarter
MNOV's operating margin has soared by 87% YoY and by 41% QoQ
The company's revenue has surged by 54% QoQ

Price vs fundamentals

How does MNOV's price correlate with its fundamentals

Growth

What is Medicinova's growth rate over time

Valuation

What is Medicinova stock price valuation
P/E
N/A
P/B
3.7
P/S
149.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
122.24
MNOV's EPS is up by 16% year-on-year and by 9% since the previous quarter
The P/B is 139% higher than the 5-year quarterly average of 1.6 and 139% higher than the last 4 quarters average of 1.6
The equity has declined by 20% year-on-year and by 5% since the previous quarter
The company's revenue has surged by 54% QoQ
The stock's P/S is 7% more than its last 4 quarters average of 145.5

Efficiency

How efficient is Medicinova business performance
MNOV's return on sales has surged by 87% year-on-year and by 41% since the previous quarter
MNOV's ROIC is down by 45% YoY
Medicinova's return on equity has decreased by 15% YoY but it has increased by 2.9% QoQ
The ROA fell by 12% YoY but it rose by 3.2% QoQ

Dividends

What is MNOV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MNOV.

Financial health

How did Medicinova financials performed over time
MNOV's current ratio is down by 34% year-on-year and by 3.7% since the previous quarter
The quick ratio has contracted by 34% YoY and by 3.7% from the previous quarter
The debt is 100% less than the equity
The debt has contracted by 37% YoY and by 29% from the previous quarter
The equity has declined by 20% year-on-year and by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.